Register Login

ATHIRA PHARMA, INC. (LONA)

(10% Negative) ATHIRA PHARMA, INC. (LONA) Announces Delay in Lasofoxifene Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 7, 2026, 8:12 p.m.

    📋 ATHIRA PHARMA, INC. (LONA) - Clinical Trial Update

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:05:49

    Event Type: Clinical Trial Update

    Event Details:

    ATHIRA PHARMA, INC. (LONA) Announces Clinical Trial Update ATHIRA PHARMA, INC. (LONA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Lasofoxifene, results
    • Clinical Stage: Phase 2, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene
    • Updated Timeline: May 7, 2025
      • Anticipated in 2H 2027

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ATHIRA PHARMA, INC.
    • Ticker Symbol: LONA

Search

News categories